David Suran | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

David Suran — Maribor University Medical Centre

David Suran
Affiliation Maribor University Medical Centre
Country Slovenia
Scopus ID 26650243300
Documents 310
Citations 332
h-index 11
Subject Area Cardiovascular Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-4073-9286

David Suran is a Slovenian clinician-scientist associated with Maribor University Medical Centre whose academic contributions focus on cardiovascular pharmacology, myocardial infarction research, renal complications in cardiovascular disease, and clinical cardiology. His published works demonstrate interdisciplinary engagement in cardiology, nephrology, internal medicine, and evidence-based cardiovascular outcomes research. Through extensive clinical investigations and collaborative medical publications, Suran has contributed to the understanding of myocardial infarction management, acute kidney injury, atrial fibrillation, cardiovascular risk assessment, and translational clinical medicine.[1]

Abstract

This academic article presents a structured overview of the research profile and scholarly contributions of David Suran in the fields of cardiovascular medicine and cardiovascular pharmacology. The article summarizes publication trends, citation indicators, collaborative clinical investigations, and thematic areas of research related to myocardial infarction, atrial fibrillation, acute kidney injury, cardiovascular outcomes, and evidence-based medicine. It further evaluates the suitability of the researcher for recognition under the Best Researcher Award category associated with the International Top Pharmaceutical Awards. The analysis reflects the researcher’s sustained participation in peer-reviewed scientific communication and clinically oriented medical investigations.[2]

Keywords

Cardiovascular Pharmacology, Myocardial Infarction, Acute Kidney Injury, Clinical Cardiology, Cardiovascular Outcomes, Internal Medicine, Atrial Fibrillation, Evidence-Based Medicine, Translational Medicine, Cardiovascular Research

Introduction

Cardiovascular diseases remain among the leading causes of global morbidity and mortality, thereby necessitating continuous scientific advancements in prevention, diagnosis, and therapeutic intervention. Clinical cardiology research plays a significant role in improving patient outcomes through observational studies, pharmacological assessments, and evidence-driven treatment approaches. David Suran has contributed to this research landscape through publications addressing cardiovascular complications, myocardial infarction management, renal impairment in cardiovascular conditions, and clinical predictors associated with adverse cardiovascular outcomes.[3]

His academic and clinical work demonstrates integration between hospital-based medical practice and scholarly research activities. Publications indexed through Scopus and ORCID indicate active participation in collaborative research initiatives involving cardiovascular medicine, nephrology, metabolic disorders, and public health-related cardiovascular investigations.[4]

Research Profile

David Suran is affiliated with Maribor University Medical Centre in Slovenia and serves in academic and clinical capacities associated with cardiology and cardiovascular medicine. ORCID records indicate involvement in internal medicine specialization, cardiovascular medicine specialization, and biomedical technology research training.[5]

The researcher’s Scopus profile records 310 documents, 332 citations, and an h-index of 11, reflecting sustained scholarly activity in cardiovascular medicine and related interdisciplinary areas. His research portfolio demonstrates thematic continuity in myocardial infarction studies, atrial fibrillation management, renal dysfunction following cardiovascular intervention, and prognostic cardiovascular biomarkers.[1]

  • Clinical specialization in cardiology and cardiovascular medicine
  • Research emphasis on myocardial infarction and cardiovascular complications
  • Peer-reviewed contributions to nephrology and cardiovascular outcomes research
  • Participation in collaborative translational medicine studies
  • Integration of evidence-based medicine within clinical cardiology practice

Research Contributions

A significant portion of Suran’s research has focused on cardiovascular risk assessment and patient outcomes in myocardial infarction populations. Publications investigating lipoprotein(a), acute kidney injury, obesity-related cardiovascular complications, and atrial fibrillation recurrence contribute to contemporary cardiovascular clinical understanding.[6]

Several studies have explored relationships between cardiovascular biomarkers and patient prognosis in acute myocardial infarction. Research addressing anemia, renal deterioration after percutaneous coronary intervention, and inflammatory or metabolic risk factors illustrates the clinical relevance of his investigations in routine medical practice.[3]

Additional investigations involving machine learning applications in medicine and explainable artificial intelligence demonstrate interdisciplinary engagement beyond traditional cardiovascular pharmacology. These contributions indicate evolving participation in digital health analytics and data-driven clinical methodologies.[3]

Publications

David Suran’s publications focus on cardiovascular pharmacology, myocardial infarction outcomes, atrial fibrillation, and renal complications associated with cardiovascular disease. His research includes clinical studies on lipoprotein(a), acute kidney injury, cardiovascular risk prediction, and interventional cardiology methodologies. Several works also examine evidence-based therapeutic approaches and translational medical applications in cardiovascular medicine.[4]

Research Impact

The scholarly contributions of David Suran demonstrate measurable academic engagement through peer-reviewed publications, interdisciplinary collaboration, and citation visibility in cardiovascular medicine. His work contributes to ongoing clinical discussions concerning myocardial infarction prognosis, cardiovascular complications, and evidence-based therapeutic approaches.[3]

Research outputs indexed in Scopus and ORCID further indicate continuity of scientific productivity and participation in internationally accessible medical literature databases. Studies involving cardiovascular risk biomarkers, renal complications, and outcome-based analyses hold practical significance for clinical cardiology and cardiovascular pharmacology research communities.[4]

Award Suitability

The Best Researcher Award recognizes individuals demonstrating sustained academic productivity, research quality, interdisciplinary collaboration, and meaningful scholarly contributions within their respective domains. David Suran’s publication profile, clinical research involvement, and documented scientific outputs indicate alignment with the evaluative expectations associated with international academic recognition programs.[4]

His research contributions to cardiovascular pharmacology and clinical cardiology demonstrate consistency in peer-reviewed dissemination, evidence-oriented investigation, and participation in clinically relevant scientific studies. The integration of cardiovascular outcomes research with practical clinical observations further strengthens the academic significance of his work within pharmaceutical and medical research communities.[4]

Conclusion

David Suran has established a research profile centered on cardiovascular medicine, myocardial infarction outcomes, and translational clinical investigations. His scholarly work reflects contributions to evidence-based cardiovascular research, interdisciplinary medical collaboration, and clinically applicable scientific inquiry. Through publications indexed in internationally recognized databases, Suran continues to contribute to the advancement of cardiovascular pharmacology and related medical sciences. The cumulative body of work supports his recognition within professional academic award frameworks focused on research excellence and clinical impact.[4]

References

  1. Elsevier. (n.d.). Scopus author details: David Suran, Author ID 26650243300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26650243300
  2. ORCID. (n.d.). David Suran ORCID profile and publication summary.https://orcid.org/0000-0002-4073-9286
  3. Suran, D. et al. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality. Diagnostics.https://doi.org/10.3390/diagnostics14232757
  4. Suran, D. et al. (2023). Obesity and Acute Kidney Injury in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine.https://doi.org/10.3390/jcm12237311
  5. ORCID. (n.d.). Professional activities and academic qualifications of David Suran.https://orcid.org/0000-0002-4073-9286
  6. Suran, D. et al. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Frontiers in Public Health.https://doi.org/10.3389/fpubh.2022.923797
  7. Suran, D. et al. (2019). Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention. Cardiorenal Medicine.https://doi.org/10.1159/000492287

Hamayak Sisakian | Cardiovascular Pharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Hamayak Sisakian | Cardiovascular Pharmacology | Research Excellence Award

Yerevan State Medical University | Armenia

Prof. Hamayak Sisakian is a distinguished Armenian cardiologist whose career reflects exceptional commitment to clinical excellence, academic leadership, and internationally recognized contributions to cardiovascular medicine. His academic foundation began at the renowned Physics-Mathematics-focused Secondary School N1 in Yerevan, after which he completed his medical education at Yerevan State Medical University with high honors, graduating with a Red Diploma. He pursued advanced clinical training in internal diseases and cardiology at YSMU’s Department of Internal Diseases N1 and the Erebouni Medical Center, establishing the groundwork for a career dedicated to advancing the science and practice of cardiac care.Prof. Sisakian’s academic career spans progressive roles, starting as an Associate Professor and later advancing to a full professorship in the Department of Internal Diseases at YSMU’s University Hospital N1. He currently serves as the Head of the Department of General and Invasive Cardiology at the same institution, where he leads clinical programs, research initiatives, and the training of new generations of cardiologists. Additionally, he is Co-Founder and Co-Director of the Ultrasound Education University Center, an esteemed educational collaboration with Thomas Jefferson University Hospital’s Jefferson Ultrasound Research and Education Institute in Philadelphia, significantly advancing diagnostic ultrasound expertise in Armenia.His research achievements include the defense of notable theses, among them Cardioprotective Effect of the Products of Lymphocytes Activity and Clinical and Pathogenetic Characteristics of Myocardial Remodeling in Idiopathic Dilated Cardiomyopathy, which contributed to strengthening cardiology research at both national and international levels.

Citation Metrics (Google Scholar)

300

200

100

50

0

Citations
280

h-index
4

i10-index
2

Citations
h-index
i10-index


View Google Scholar Profile

Featured Publications

Mahshid Malakootian | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mahshid Malakootian | Cardiovascular Pharmacology | Best Researcher Award

Assoc. Prof. Dr Mahshid Malakootian, Rajaie cardiovascular medical and research center, Iran

Born on March 21, 1981, in Tehran, Iran, Dr. Mahshid Malakootian is a distinguished molecular geneticist and Associate Professor at Rajaie Cardiovascular Medical & Research Institute, Tehran. A prolific researcher, she specializes in non-coding RNAs, cardiovascular genetics, and bioinformatics. She completed her Ph.D. in Molecular Genetics at Tarbiat Modares University and held postdoctoral fellowships at McGill University and Case Western Reserve University. Dr. Malakootian has published extensively and received numerous accolades, including Best Young Researcher awards. Fluent in English and Persian, she is a dedicated academic, head of the Cardiogenetic Research Center, and an editorial board member. 📚🧬🌍

Publication Profile

google scholar

Academic Excellence

Assoc. Prof. Dr. Mahshid Malakootian is a distinguished expert in molecular genetics and cardiogenetics, contributing significantly to the field. Since 2021, she has served as an Associate Professor at the Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran, Iran. 💡 From 2018, she has led the center as its Head, advancing groundbreaking research in cardiovascular genetics. 🧬 Previously, she was an Assistant Professor from 2015 to 2021 and has been an active board member of the Research Deputy since 2015, shaping impactful scientific initiatives. 📚 Her work continues to drive innovation in cardiovascular health. ❤️

Research Experience

Assoc. Prof. Dr. Mahshid Malakootian is an accomplished molecular geneticist with extensive research experience. She pursued her post-doctorate in Experimental Medicine at McGill University, Canada (2016-2017), focusing on PCSK7 RNA regulators 🧬. Previously, she was a post-doctoral fellow at Tarbiat Modares University, Tehran (2014-2015), and a visiting research scholar at Case Western Reserve University, USA (2011-2012) 🔬. Dr. Malakootian earned her Ph.D. (2009-2014) and M.Sc. (2004-2007) in Molecular Genetics at Tarbiat Modares University, where she explored non-coding RNAs and tumorigenesis. Her academic journey began with a B.Sc. in Cellular and Molecular Sciences from the University of Tehran (1999-2003) 🧪.

Honors and Awards

Assoc. Prof. Dr. Mahshid Malakootian is an award-winning researcher recognized for her outstanding contributions in molecular genetics and stem cell technology. 🏆 She has earned accolades such as the “Best Young Researcher” award (2017, 2019) and the “Top Thesis Award” (2014). 🎖 Her pioneering research is supported by multiple grants, including studies on noncoding RNAs and cardiovascular biomarkers. She has discovered and sequenced numerous novel genetic variants, published in GenBank, and co-authored a U.S. patent for miR-her2-1, aiding breast and ovarian cancer diagnostics. 💡📚 A scholar of exceptional caliber, Dr. Malakootian remains a trailblazer in biomedical innovation. 🌟

Professional Societies

Assoc. Prof. Dr. Mahshid Malakootian is an accomplished scientist and an active member of prestigious organizations, including the American Association for Cancer Research (AACR) 🌟, the Iranian Genetics Society (IGS) 🧬, and the Iranian Biotechnology Society 🌿. Her dedication to advancing research is reflected in her role as an editorial board member of the Environmental Health Engineering and Management Journal 📚. With her extensive expertise and contributions, she continues to shape the fields of cancer research, genetics, and biotechnology, fostering innovative solutions for global health challenges 🌍. Dr. Malakootian’s work exemplifies excellence and inspires the scientific community. ✨

Teaching Experience

Associate Professor Dr. Mahshid Malakootian is a distinguished expert in molecular genetics at Shahed University, where she also leads the Advanced Molecular Genetics Lab Course 🧬. Her dedication to education and research has inspired countless students and colleagues. Dr. Malakootian has honed her expertise as a research assistant in Dr. Mowla’s laboratory, contributing to cutting-edge discoveries in molecular genetics 🔬. With a passion for advancing knowledge, she has made significant strides in her field, combining academic excellence with hands-on laboratory experience. Her work continues to shape the future of genetic research and education, making her a respected figure in the scientific community.

Research Focus

Assoc. Prof. Dr. Mahshid Malakootian focuses on cutting-edge research in microRNAs, cardiovascular diseases, and non-coding RNAs in various biological and pathological contexts. Her work explores microRNA roles in cardiovascular development, post-transcriptional regulation, and cancer biology, particularly lung and esophageal tumors. Dr. Malakootian also investigates long non-coding RNAs (lncRNAs), circular RNAs, and their interplay in genetic regulation and disease pathways. Her studies on epigenetics and innovative therapeutic approaches significantly impact cardiovascular health and cancer treatment. 🧬🩺🫀

Publication Top Notes

MicroRNAs: roles in cardiovascular development and disease

Post-transcriptional regulation of PCSK9 by miR-191, miR-222, and miR-224

Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors

Ciprofloxacin removal from aqueous media by adsorption process: a systematic review and meta-analysis

Pathophysiology, Diagnosis, Treatment, and Genetics of Carpal Tunnel Syndrome: A Review

Linc-ROR and its spliced variants 2 and 4 are significantly up-regulated in esophageal squamous cell carcinoma

Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report

Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors

lncRNA PSORS1C3 is regulated by glucocorticoids and fine-tunes OCT4 expression in non-pluripotent cells